Nasal lymphoma is the most common nasal tumor in cats and is generally a solitary and
radiosensitive tumor. We retrospectively evaluated the response to radiation and survival
time in relation to apoptosis and Ki-67 indices in feline nasal lymphomas treated with
radiation therapy. The apoptotic and Ki-67 indices were evaluated with TUNEL and
immunohistochemical staining in 30 biopsy tissues that were taken before any treatment.
These two indices were compared, and differences between different treatment response
groups were analyzed. The correlation between the median survival times (MST) and the
indices was estimated using the Kaplan Meier method, and statistical differences between
survival curves were analyzed using a log-rank method. With regard to apoptotic index, a
statistical difference was observed between the samples taken from cats with complete
response and stable disease (1.22% vs. 0.45%; P=0.045). The Ki-67 index
in cats with both complete response and partial response was significantly higher than in
cats with stable disease (44.4% and 39.6% vs. 16.3%; P<0.001 and
P=0.008, respectively). The cats with a high level of apoptosis
(>0.9%) nasal lymphoma were not significantly prolonged MSTs
(P=0.202), however, high Ki-67-positive (>40%) cats experienced a
statistically significant relationship with longer survival time
(P=0.015). Our results indicate that spontaneous apoptotic and Ki-67
indices are strong predictors for response to radiation therapy in feline nasal
lymphomas.
Apoptosis, Ki-67 and survivin
expression have been reported as prognostic values in human cancer treated with radiation
therapy. The aim of this study was to evaluate the correlation between the outcome of
canine nasal carcinomas treated with radiation therapy and these cancer markers. The
apoptotic index (AI) was evaluated with TUNEL assays, and an immunohistochemical
evaluation was performed on Ki-67 and survivin in 33 biopsy samples taken before
treatment. Median survival times were estimated using Kaplan-Meier curves and the log-rank
method. The AI ranged from 0 to 0.7%, and the percentage of Ki-67-positive cells defined
as the proliferative index (PI) ranged from 0.8 to 77% in all samples. Neither the AI nor
the PI had a significant relationship with survival time (P=0.056 and
0.211). Survivin expression was detected in 84.9% of samples of canine nasal carcinoma.
Dogs with high survivin expression were associated with poorer response to treatment and
had shorter survival times (P=0.017 and 0.031). Advanced-stage tumors
were also significantly associated with a high level of survivin
(P=0.026). Overexpression of survivin was shown to be an unfavorable
prognostic factor in dogs with nasal carcinomas treated with radiation therapy.
ABSTRACT. To evaluate the relationship among immune status and increased morbidity and mortality, peripheral blood lymphocytes (CD3 + , CD4 + , CD8 + and CD21 + cells) from 32 healthy dogs over 8 years of age were analyzed. Twenty-five of the 32 dogs were followed-up for 3 years after the analysis; and 14 dogs were found to be diseased, and nine dogs died. There was no notable difference between the ages of the dogs that died compared with the ones that survived. The relative percentage of CD4 + and the CD4 + :CD8 + ratio decreased notably in dogs falling ill compared with healthy dogs. The relative percentage of CD3 + lymphocytes showed a notable decrease in dogs that died within 3 years in comparison with dogs that survived. In a discriminant analysis of morbidity and mortality, most patients were correctly classified as diseased or not and surviving or dead, respectively. These results indicate that the immunophenotypes of peripheral blood lymphocytes in older dogs offer promise as parameters for evaluating mortality and morbidity.
ObjectiveTo compare the occurrence of radiation side effects and treatment outcomes in dogs with intranasal tumors treated with a total dose of 20 Gy delivered in 5 daily 4 Gy fractions using computer-based 3D conformal (3DCRT) or intensity-modulated (IMRT) radiation therapy plans.DesignRetrospective case series.Materials and methodsMedical records for dogs with intranasal tumors treated with 4 Gy × 5 fractions between 2010 and 2017 were reviewed. Radiation side effects, time to local progression (TTLP), progression-free survival (PFS) and survival time (OS) were evaluated.ResultsThirty-six dogs (24 carcinomas, 10 sarcomas and 2 others) met the inclusion criteria. Sixteen were treated with 3DCRT and 20 with IMRT. Clinical signs improvement or resolution were reported in 84% of dogs. The median time to clinical signs improvement was 12 days (1–88 days) after the end of treatment. Eight dogs treated with 3DCRT (8/16, 50%) and 5 with IMRT (5/20, 25%) were documented acute radiation side effects. Almost all were classified as grade 1 skin, oral or ocular acute side effects. Only one dog in 3DCRT group was demonstrated grade 2 skin acute effects. The median TTLP for dogs treated with 3DCRT or IMRT was 238 days and 179 days, respectively (p = 0.967). The median PFS for 3DCRT or IMRT was 228 days and 175 days, respectively (p = 0.940). The median OS for 3DCRT or IMRT was 295 days and 312 days, respectively (p = 0.787). No significantly differences were observed in side effects, TTLP, PFS and OS between 3DCRT and IMRT groups.ConclusionsPalliative-intent conformal radiation therapy given in five daily 4 Gy fractions relieved clinical signs with minimal radiation side effects, with no statistical difference in occurrence between 3DCRT and IMRT dogs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.